Landmark Bio Begins Construction on Biopharmaceutical Research and Manufacturing Facility
Landmark Bio began construction in July of 2021 on a leased facility in Watertown, Mass. Supported by $76 million in funding, the 40,000-sf project will accelerate the availability of novel therapeutics by collocating research, development, manufacturing, and commercialization activities in the same structure. Featuring eight GMP cleanrooms configured to allow production of both cell and viral vector materials, the center will include labs, offices, and quality control suites.